Q2 Earnings Forecast for RVPH Issued By Zacks Research

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities researchers at Zacks Research issued their Q2 2026 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued to investors on Wednesday, May 27th. Zacks Research analyst J. Vandermosten forecasts that the company will earn ($0.36) per share for the quarter. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($2.96) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ Q3 2026 earnings at ($0.55) EPS, Q4 2026 earnings at ($0.55) EPS and FY2028 earnings at ($0.51) EPS.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10).

A number of other brokerages also recently issued reports on RVPH. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Maxim Group downgraded shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. D. Boral Capital downgraded shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.67.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ RVPH opened at $0.38 on Thursday. The company has a market capitalization of $5.02 million, a P/E ratio of -0.09 and a beta of 0.75. Reviva Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $23.00. The company’s 50 day moving average price is $0.78 and its 200-day moving average price is $5.24.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Reviva Pharmaceuticals by 87.6% in the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after acquiring an additional 489,711 shares in the last quarter. Millennium Management LLC increased its stake in shares of Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after acquiring an additional 223,178 shares in the last quarter. Armistice Capital LLC bought a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter valued at $1,026,000. XTX Topco Ltd increased its stake in shares of Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after acquiring an additional 63,893 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after acquiring an additional 256,500 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.